• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Reduced SARS-CoV-2 mRNA vaccine immunogenicity and protection in mice with diet-induced obesity and insulin resistance
CONCLUSION: We demonstrate impaired immunity following SARS-CoV-2 mRNA immunization in a murine model of comorbid T2DM and obesity, supporting the need for further research into the basis for impaired anti-SARS-CoV-2 immunity in T2DM and investigation of novel approaches to enhance vaccine immunogenicity among those with metabolic diseases.PMID:37595760 | DOI:10.1016/j.jaci.2023.06.031
Source: Clinical Lung Cancer - August 18, 2023 Category: Cancer & Oncology Authors: Timothy R O'Meara Etsuro Nanishi Marisa E McGrath Soumik Barman Danica Dong Carly Dillen Manisha Menon Hyuk-Soo Seo Sirano Dhe-Paganon Robert K Ernst Ofer Levy Matthew B Frieman David J Dowling Source Type: research

The Conspirituality of Robert F. Kennedy Jr.
This article has been adapted from Chapter 23 of Conspirituality: How New Age Conspiracy Theories Became a Health Threat by Derek Beres, Matthew Remski, and Julian Walker. Copyright © 2023. Available from PublicAffairs, an imprint of Hachette Book Group, Inc.
Source: TIME: Health - July 5, 2023 Category: Consumer Health News Authors: Derek Beres, Matthew Remski, and Julian Walker Tags: Uncategorized freelance politics Source Type: news

Updated Guidance Regarding The Risk ofAllergic Reactions to COVID-19 Vaccines and Recommended Evaluation and Management: A GRADE Assessment, and International Consensus Approach
J Allergy Clin Immunol. 2023 Jun 7:S0091-6749(23)00746-7. doi: 10.1016/j.jaci.2023.05.019. Online ahead of print.ABSTRACTThis guidance updates 2021 GRADE recomendations regarding immediate allergic reactions following COVID-19 vaccines and addresses re-vaccinating individuals with 1st dose allergic reactions and allergy testing to determine re-vaccination outcomes. Recent meta-analyses assessed the incidence of severe allergic reactions to initial COVID-19 vaccination, risk of mRNA-COVID-19 re-vaccination after an initial reaction, and diagnostic accuracy of COVID-19 vaccine and vaccine excipient testing in predicting reac...
Source: Clinical Lung Cancer - June 9, 2023 Category: Cancer & Oncology Authors: Matthew Greenhawt Timothy E Dribin Elissa M Abrams Marcus Shaker Derek K Chu David Bk Golden Cem Akin Akterini Anagnostou Faisal ALMuhizi Waleed Alqurashi Peter Arkwright James L Baldwin Aleena Banerji Philippe B égin Moshe Ben-Shoshan Jonathan Bernstein Source Type: research

The COVID-19 virus mutated to outsmart key antibody treatments. Better ones are coming
In 2020, as the COVID-19 pandemic raged and other effective drugs were elusive, monoclonal antibodies (mAbs) emerged as a lifesaving treatment. But now, 3 years later, all the approvals for COVID-19–fighting antibodies have been rescinded in the United States, as mutations of the SARS-CoV-2 virus have left the drugs—which target parts of the original virus—ineffective. Researchers around the globe are now trying to revive antibody treatments by redesigning them to take aim at targets that are less prone to mutation. “There are new approaches that present a much more challenging task for the virus to evade,” ...
Source: ScienceNOW - May 24, 2023 Category: Science Source Type: news

Science ’s 2022 Breakthrough of the Year: A telescope’s golden eye sees the universe anew
html { scroll-behavior: smooth; } .news-article-content--featured>.bodySection>.mb-2x:not(:first-of-type) { display: none; } h3 { scroll-margin-top: 5rem; } .parent-section h3, .subsection h3 { font-size: 1.375rem; line-height: 1.875rem; } .news-article-content-footer h2 { display: none; } .toc img { padding-bottom: 16px; transition: opacity .25s; } .toc img:hover { opacity: 60%; } .toc .image-grid img { padding-bottom: 16px; padding-top: 16px; } .image-grid .news-article__figure__image__wrapper:before, .image-grid .news-article__figure__image__wrapper:after { display: none; } .news-article-content sectio...
Source: ScienceNOW - December 15, 2022 Category: Science Source Type: news

U.S. weighs crackdown on experiments that could make viruses more dangerous
.news-article__hero--featured .parallax__element{ object-position: 50% 40%; -o-object-position: 50% 40%; } .scroll-wrapper { overflow-x: auto; } .scroll-wrapper .news-article__figure__image{ width: 2680px; max-width: none; padding-bottom: .75rem; } .scroll-fade-before, .scroll-fade-after { position: absolute; width: 1.5rem; transition-duration: .1s; opacity: 1; } .scroll-fade-before { left: 1rem; /*margin-left: -1px;*/ background: linear-gradient(90deg, #fff, #fff 35%, hsla(0, 0%, 100%, 0)); } .scroll-fade-after { right: 1rem; /*margin-right: -1px;*/ background: linear-gradient(270deg, #fff, #fff 35%, hsla(0,...
Source: ScienceNOW - October 19, 2022 Category: Science Source Type: news

Why efforts to make better, more universal coronavirus vaccines are struggling
There’s a new call from the White House to develop vaccines that might protect against future SARS-CoV-2 mutants or even unknown coronaviruses. “The vaccines we have are terrific, but we can do better than terrific,” Ashish Jha, White House COVID-19 response coordinator, said at a vaccine summit yesterday that gathered researchers, companies, and government officials. “Ultimately, we need vaccines that can protect us no matter what Mother Nature throws at us.” But no specific funding request to Congress was revealed at the summit, or any concrete plans, so vaccine developers and the public shouldn’t expect...
Source: Science of Aging Knowledge Environment - July 27, 2022 Category: Geriatrics Source Type: research

SARS-CoV-2 omicron: Light at the end of the long pandemic tunnel or another false dawn for immunodeficient patients?
J Allergy Clin Immunol Pract. 2022 Jun 22:S2213-2198(22)00597-9. doi: 10.1016/j.jaip.2022.06.011. Online ahead of print.ABSTRACTCOVID-19 has had a disastrous impact on the world. Apart from at least 6 million deaths, countless COVID-19 survivors are suffering long-term physical and psychiatric morbidity. Hundreds of millions have been plunged into poverty caused by economic misery, particularly in developing nations. Early in the pandemic, it became apparent certain groups of individuals such as the elderly and those with comorbidities were at increased risk of severe disease. In addition, patients with some forms of immun...
Source: Clinical Lung Cancer - June 25, 2022 Category: Cancer & Oncology Authors: Rohan Ameratunga Euphemia Leung See-Tarn Woon Lydia Chan Richard Steele Klaus Lehnert Hilary Longhurst Source Type: research

News at a glance: China ’s carbon pledge, ARPA-H’s interim head, and an exascale computer
Some content has been removed for formatting reasons. Please view the original article for the best reading experience. Table of contents A version of this story appeared in Science, Vol 376, Issue 6597. Download PDF CONSERVATION U.S. moves to stop Alaska copper mine The U.S. Environmental Protection Agency (EPA) is moving to block construction of a massive copper and gold mine that would risk polluting the headwaters of Alaska’s Bristol Bay, home to the world’s largest sockeye salmon runs. EPA announced last week it plans to forbid dis...
Source: Science of Aging Knowledge Environment - June 2, 2022 Category: Geriatrics Source Type: research

Predictors of seroconversion following COVID-19 vaccination
CONCLUSION: Vaccine responses vary by age and sex, with males showing lower rates of seroconversion as compared to females. Primary immunodeficiency along with active malignancy and ongoing immunosuppression with steroids and/or B-cell depletion therapy appeared to be the most common characteristics for those with lack of vaccine seroconversion following COVID-19 vaccination.PMID:35640775 | PMC:PMC9144839 | DOI:10.1016/j.anai.2022.05.026
Source: Annals of Allergy, Asthma and Immunology - May 31, 2022 Category: Allergy & Immunology Authors: Sergio E Chiarella Sarah M Jenkins Carin Y Smith Vikas Prasad Fnu Shakuntulla Vaibhav Ahluwalia Vivek N Iyer Elitza S Theel Avni Y Joshi Source Type: research

Novel COVID-19 Vaccine for Patients With Blood Cancers Novel COVID-19 Vaccine for Patients With Blood Cancers
A novel vaccine (CoVac-1) currently in clinical trials in Germany induced T-cell immune responses in a large proportion of patients with blood cancers and B cell deficiencies.Medscape Medical News
Source: Medscape Allergy Headlines - April 19, 2022 Category: Allergy & Immunology Tags: Hematology-Oncology News Source Type: news

Defining the risk of SARS-CoV-2 variants on immune protection
We report the development of reagents, methodologies, models, and pivotal findings facilitated by this collaborative approach and identify future challenges. This program serves as a template for the response against rapidly evolving pandemic pathogens by monitoring viral evolution in the human population to identify variants that could erode the effectiveness of countermeasures.PMID:35361968 | DOI:10.1038/s41586-022-04690-5
Source: Cancer Control - April 1, 2022 Category: Cancer & Oncology Authors: Marciela M DeGrace Elodie Ghedin Matthew B Frieman Florian Krammer Alba Grifoni Arghavan Alisoltani Galit Alter Rama R Amara Ralph S Baric Dan H Barouch Jesse D Bloom Louis-Marie Bloyet Gaston Bonenfant Adrianus C M Boon Eli A Boritz Debbie L Bratt Traci Source Type: research

What to Know About a Fourth COVID-19 Vaccine Dose
Most people ages 12 and older are considered “up to date” with their COVID-19 vaccines if they received either three doses of the mRNA shots from Pfizer-BioNTech or Moderna, or two doses of Johnson & Johnson’s Janssen vaccine. But some public health experts say another dose might be needed in the coming months. The Washington Post reports today that Pfizer and BioNTech soon plan to request authorization from the U.S. Food and Drug Administration (FDA) for a fourth dose of their vaccine in people ages 65 and older. In the past few days, Albert Bourla, Pfizer’s CEO, has said that he believes every...
Source: TIME: Health - March 15, 2022 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized COVID-19 healthscienceclimate Source Type: news

NIDCR's Spring 2022 E-Newsletter
Having trouble viewing this email? View it as a Web page. NIDCR's Spring 2022 E-Newsletter In this issue: NIDCR News Funding Opportunities & Related Notices NIH/HHS News Subscribe to NIDCR News Science Advances   NIDCR News NIH & NIDCR Release “Oral Health in America: Advances and Challenges” In December, NIDCR announced the release of a report that provides a comprehensive snapshot of oral health in America, detailing 20 years of advances and challenges and drawing on data from public research and evidence-based practices. For more ...
Source: NIDCR Science News - March 3, 2022 Category: Dentistry Source Type: news